PMID- 25746375
OWN - NLM
STAT- MEDLINE
DCOM- 20160105
LR  - 20150413
IS  - 1879-1484 (Electronic)
IS  - 0021-9150 (Linking)
VI  - 240
IP  - 1
DP  - 2015 May
TI  - Nebivolol to attenuate the effects of hyper-homocysteinaemia in rats.
PG  - 33-9
LID - S0021-9150(15)00145-8 [pii]
LID - 10.1016/j.atherosclerosis.2015.02.054 [doi]
AB  - OBJECTIVE: This study investigated the prophylactic effect of nebivolol against 
      hyper-homocysteinaemia (hHcy) induced oxidative stress in brain, heart, liver and 
      kidney tissues and histomorphometric changes in the thoracic aorta. METHODS: 
      Twenty-four adult male Wistar rats were divided into a control, nebivolol, hHcy 
      and nebivolol+hHcy group. hHcy was induced by oral administration of L-methionine 
      (1 g/kg/day) for 28 days. 10 mg/kg/day nebivolol was administered orally for 28 
      days. Malondialdehyde (MDA) and glutathione (GSH) levels and catalase (CAT) and 
      superoxide dismutase (SOD) activities in the tissues were determined. The total 
      cross-sectional area (TCSA), luminal cross-sectional area (LCSA) and intima-media 
      thickness (IMT) were measured in the thoracic aorta. RESULTS: Homocysteine (Hcy) 
      levels were lower in the nebivolol+hHcy group than in the hHcy group. Nebivolol 
      treatment significantly decreased high MDA levels in the brain, heart and liver 
      tissues. The level of GSH was higher in the brain, heart and kidney tissues of 
      the nebivolol+hHcy group (P<0.001). The activity of CAT increased only in the 
      kidney tissue of the nebivolol+hHcy group (P<0.01), and the activity of SOD was 
      significantly increased in all the tissues in this group. Increased TCSA and IMT 
      in the nebivolol+hHcy group were significantly decreased after nebivolol 
      administration. The LCSA was significantly higher in the hHcy group than the 
      control group, probably due to outward vascular remodelling. CONCLUSION: 
      Nebivolol treatment may be useful in different clinical scenarios where hHcy 
      affects physiopathological pathways.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Akgullu, Cagdas
AU  - Akgullu C
AD  - Department of Cardiology, Faculty of Medicine, Adnan Menderes University, Aydin, 
      Turkey. Electronic address: cagdasakgullu@gmail.com.
FAU - Huyut, Mustafa Ahmet
AU  - Huyut MA
AD  - Department of Cardiology, Aydin City Hospital, Aydin, Turkey.
FAU - Boyacioglu, Murat
AU  - Boyacioglu M
AD  - Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Adnan 
      Menderes University, Aydin, Turkey.
FAU - Gules, Ozay
AU  - Gules O
AD  - Department of Histology and Embryology, Faculty of Veterinary Medicine, Adnan 
      Menderes University, Aydin, Turkey.
FAU - Eryilmaz, Ufuk
AU  - Eryilmaz U
AD  - Department of Cardiology, Faculty of Medicine, Adnan Menderes University, Aydin, 
      Turkey.
FAU - Hekim, Tolga
AU  - Hekim T
AD  - Department of Cardiology, Aydin City Hospital, Aydin, Turkey.
FAU - Dogan, Emir
AU  - Dogan E
AD  - Department of Cardiology, Ada Tip Hospital, Sakarya, Turkey.
FAU - Zencir, Cemil
AU  - Zencir C
AD  - Department of Cardiology, Faculty of Medicine, Adnan Menderes University, Aydin, 
      Turkey.
FAU - Gungor, Hasan
AU  - Gungor H
AD  - Department of Cardiology, Faculty of Medicine, Adnan Menderes University, Aydin, 
      Turkey.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20150228
PL  - Ireland
TA  - Atherosclerosis
JT  - Atherosclerosis
JID - 0242543
RN  - 0 (Antioxidants)
RN  - 0 (Biomarkers)
RN  - 030Y90569U (Nebivolol)
RN  - 4Y8F71G49Q (Malondialdehyde)
RN  - AE28F7PNPL (Methionine)
RN  - EC 1.11.1.6 (Catalase)
RN  - EC 1.15.1.1 (Superoxide Dismutase)
RN  - GAN16C9B8O (Glutathione)
SB  - IM
MH  - Animals
MH  - Antioxidants/*pharmacology
MH  - Aorta, Thoracic/drug effects/metabolism/pathology
MH  - Biomarkers/metabolism
MH  - Brain/drug effects/metabolism
MH  - Catalase/metabolism
MH  - Cytoprotection
MH  - Disease Models, Animal
MH  - Glutathione/metabolism
MH  - Hyperhomocysteinemia/chemically induced/complications/*drug therapy
MH  - Kidney/drug effects/metabolism
MH  - Liver/drug effects/metabolism
MH  - Male
MH  - Malondialdehyde/metabolism
MH  - Methionine
MH  - Myocardium/metabolism
MH  - Nebivolol/*pharmacology
MH  - Oxidative Stress/*drug effects
MH  - Rats, Wistar
MH  - Superoxide Dismutase/metabolism
MH  - Time Factors
MH  - Vascular Remodeling/drug effects
OTO - NOTNLM
OT  - Aorta
OT  - Hyper-homocysteinaemia
OT  - Nebivolol
OT  - Oxidant/anti-oxidant parameters
OT  - Rats
EDAT- 2015/03/10 06:00
MHDA- 2016/01/06 06:00
CRDT- 2015/03/10 06:00
PHST- 2014/10/27 00:00 [received]
PHST- 2015/02/13 00:00 [revised]
PHST- 2015/02/21 00:00 [accepted]
PHST- 2015/03/10 06:00 [entrez]
PHST- 2015/03/10 06:00 [pubmed]
PHST- 2016/01/06 06:00 [medline]
AID - S0021-9150(15)00145-8 [pii]
AID - 10.1016/j.atherosclerosis.2015.02.054 [doi]
PST - ppublish
SO  - Atherosclerosis. 2015 May;240(1):33-9. doi: 
      10.1016/j.atherosclerosis.2015.02.054. Epub 2015 Feb 28.